about
Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features.Tracking genomic cancer evolution for precision medicine: the lung TRACERx studyAssociation of invasion-promoting tenascin-C additional domains with breast cancers in young women.Circulating free DNA in the management of breast cancer.Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodesDetection of HER2 amplification in circulating free DNA in patients with breast cancer.Influence of plasma processing on recovery and analysis of circulating nucleic acids.The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy.Microsatellite instability in early sporadic breast cancer.The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancerIntrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion.Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo.Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanismsNumerical chromosomal aberrations in Hodgkin's disease detected by in situ hybridisation on routine paraffin sections.Hide and seek: tell-tale signs of breast cancer lurking in the blood.Telomere maintenance in soft tissue sarcomasTracking the Evolution of Non-Small-Cell Lung Cancer.The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring.The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.LMTK3 is implicated in endocrine resistance via multiple signaling pathways.Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells.Molecular pathology of breast cancer and its application to clinical management.Genomic instability in pre-neoplastic colonic lesions.The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas.Vitamin C supplementation in normal subjects reduces constitutive ICAM-1 expression.Altered myoepithelial cell expression and function in cancer-containing breasts.Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR.Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene.NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.Circulating tumour-derived DNA in metastatic soft tissue sarcoma.
P50
Q28360494-754A12B1-9E51-4AD2-9550-88F3891B6C2EQ28655985-C76210AA-2E4C-4305-91EC-FC551C19C1B1Q34173505-DE08B421-D2DE-4074-B346-A1BDA9DBBD27Q34357893-8687121A-E168-4C53-A0B3-139F8C889472Q34784863-BD6EE9D8-76A2-4544-BBEB-C7FA77A0D0A4Q34806810-A01DAF0A-B90B-4BF3-B57E-2F52AA1DDBB0Q35035846-402B1458-FCE8-4D5A-979A-77ECF49619CAQ35681975-E00FC090-BE3F-4EDE-B2DE-02E881916DB5Q36135111-AEAB608C-30EC-4562-B361-B579F6EC83BEQ36355823-0BC6D62B-4566-4535-A734-193C3E6AC15EQ36458763-E50819AD-FAFE-4742-BF4B-80A3994D415DQ36922505-E63D1C71-8924-4084-8097-D5272A868A64Q37208797-AE688074-8CD7-48DC-9E35-BF1947DFECF0Q37209567-A809BF36-DA99-4D82-B3CD-DD087A8D0DBDQ38056383-45425355-10D8-4BD9-AA28-42D8C0ED3C78Q38759188-93FDC825-E988-433F-8A7C-FE765520F05CQ38818761-13344EFD-93CD-4445-93FF-32EC5C19C0C1Q38825179-DE141B76-3D69-49D5-AAE4-D3363F23AA3BQ38835363-BB6B056B-DB31-452F-826C-EBD7D0461B9EQ38964312-F8A9D88C-ACE2-4B35-962C-5FBAA03B9FBFQ38987139-E078BF7A-3CBC-4BC6-841E-A9427EA941D5Q39183864-A2B32E8C-4820-4E38-B59C-093D4E7BE1E2Q39184012-BA1CFCEC-B760-4164-BD89-44C22933135AQ39301431-6175D327-6B45-4E92-A159-FEE832ECE51AQ40280975-1389C387-DDC3-40F1-9155-53F748BD653AQ40427450-C425B4B4-BC39-4DBC-B124-C3556A2C83C1Q40612563-1DD3EEA9-9FFD-497C-82A7-2331B45D10C5Q41474848-282F0C58-0092-4A39-96C1-9DC5A3D288C4Q41884150-4F78FB04-D8D6-470B-84AE-C008C68E4086Q42643973-26BCDA35-021F-48B0-8360-359CD2EA215FQ43583310-9DFAF5F4-2336-4A6B-8EEC-2BED9CE8B0C2Q44218346-F95AA4E7-D982-4C4F-99F8-6FDB67C5B32CQ44539001-1B197D32-3721-4FCE-BBD1-F21FAAB84486Q45782177-49656D25-20B6-43E4-81EF-E34B367A9AEDQ45901388-B932D582-6DCB-469A-AE7A-0304C0AC3BF8Q46365334-DA4CB14E-69D6-48F8-9AAC-649847EE1F61Q46943398-09681EA1-1802-4E91-9319-1F33FC9F1790Q47869139-216DEC24-3B06-42E5-B738-89F8DBA21C4EQ48059912-6957CD64-0885-455F-825D-621D6898B91BQ52356767-5B507771-320E-413F-9CD6-531CC5292EF5
P50
description
researcher ORCID ID = 0000-0003-4227-503X
@en
name
Jacqui A Shaw
@ast
Jacqui A Shaw
@en
Jacqui A Shaw
@es
Jacqui A Shaw
@nl
type
label
Jacqui A Shaw
@ast
Jacqui A Shaw
@en
Jacqui A Shaw
@es
Jacqui A Shaw
@nl
prefLabel
Jacqui A Shaw
@ast
Jacqui A Shaw
@en
Jacqui A Shaw
@es
Jacqui A Shaw
@nl
P1153
55250445400
7403897997
P31
P496
0000-0003-4227-503X